ClinicalTrials.gg
CompletedNCT00549913Updated Jun 29, 2020

Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)

A Phase 1/2 interventional study of NeoFuse and posterolateral spinal fusion with instrumentation in Degenerative Disc Disease, Spondylolisthesis and Spinal Stenosis, sponsored by Mesoblast, Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by Mesoblast, Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
118th of 141
6 · median 57
Started
2007
with 6 others
Phase 1/2
8 of 232
1 open now
Registered
15th of 232
by date
Lead sponsor
6 of 232
Mesoblast, Ltd.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 118th largest by enrollment of the 141 interventional ones that give a count, is one of 7 that started in 2007, is one of 8 in phase 1/2, and was the 15th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, dose escalation clinical study to evaluate the feasibility, safety, and tolerability of 3 different doses of immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) when combined with MasterGraft Resorbable Ceramic Granules (Medtronic Sofamor Danek USA, Inc.) compared to autograft in patients requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage (to be used with autologous bone graft material) and 1 or 2 level posterolateral lumbar fusion surgery with instrumentation. The instrumentation used for this study will be the Monarch® 5.50 mm Spine System (DePuy).

Read the detailed description

This is a prospective, single center, randomized, open-label controlled Phase 1b/2a study designed to evaluate the safety and preliminary efficacy of MPCs combined with MasterGraft Granules when compared to use of autologous bone graft in the posterolateral fusion site in subjects requiring interbody fusion in combination with instrumented 1 or 2 level PLF procedure. All subjects in this study will undergo a 1 or 2-level (2 or 3 vertebrae) interbody fusion without the use of the investigational product.

In addition to the interbody fusion procedure, subjects will undergo an instrumented posterolateral fusion. NeoFuse plus MasterGraft Granules at one of three doses or autograft will be implanted in the posterolateral lumbar fusion site(s) only.

After the screening and surgical visits, each subject will be evaluated clinically and radiographically within 3 days and 30 days after surgery, and at 3, 6, and 12 months after surgery.

Subjects will be evaluated at 24 and 36 months after surgery for safety.

03

Conditions studied

  • Degenerative Disc Disease
  • Spondylolisthesis
  • Spinal Stenosis

Keywords

  • adjacent vertebral levels between L1 and S1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age.
  2. Have a documented symptomatic diagnosis of DDD at L1-S1 with or without stenosis and with or without up to and including Grade II degenerative spondylolisthesis.
  3. May also have coexistent spinal or foraminal stenosis as confirmed by MRI or CT evaluation.
  4. Must have clinical symptoms of neurogenic claudication.
  5. Must have failed 6 months of nonoperative management.
  6. Must be a candidate for lumbar interbody fusion in combination with posterolateral lumbar fusion with the use of autograft from the iliac crest requiring a 1 or 2-level fusion of adjacent vertebral levels between L1 and S1.
  7. Must have a stable screening (ECG), as determined by the investigator that would not preclude surgery.

Exclusion criteria

Exclusion Criteria:

  1. Is pregnant or breastfeeding.
  2. Has Grade III or greater spondylolisthesis.
  3. Has or is undergoing revision of a prior fusion at the involved levels.
  4. Has a history of or anaphylactic reaction to murine or bovine products, dimethyl sulfoxide (DMSO), or titanium.
  5. Has MRI or CT that shows greater than 50% anterior translocation of cranial vertebral body or greater than 20 degree angular motion of the listhesis segment.
  6. Has a history of active in the last 5 years, other than basal cell carcinoma.
  7. Has osteoporosis as defined by a dual energy x-ray absorptiometry (DXA T) score of ≤ -3.5 or a history of fragility fractures or other significant bone disease contraindicating the use of spinal instrumentation.

    Note: subjects will be screened using the Simple Calculated Osteoporosis Risk Evaluation (SCORE) osteoporosis questionnaire.

  8. Has a history of Paget's disease of the spine, osteomalacia, or any other metabolic bone disease.
  9. Has a history of prior radiotherapy to the involved area.
  10. Has received systemic at a dose equivalent to prednisone > 10 mg/day within 14 days prior to study procedure.
  11. Has received systemic nonsteroidal anti-inflammatory drugs (NSAIDS) within 48 hours prior to study procedure, and unwilling to refrain from NSAIDS for the first 6 months following the procedure.
  12. Has a positive screen for (HIV) antibodies.
  13. Has had treatment with any therapy administered within 6 months before implantation surgery. .
  14. Is the prior recipient of allogeneic stem cell/progenitor cell therapy.
  15. Has a (BMI) > 3.5
  16. Has 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody specificities to donor HLA antigens.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    1

    10 subjects to receive lowest dose of NeoFuse (MPCs)

    Biological: NeoFuse

  • Active comparator
    2

    4 subjects standard posterolateral spinal fusion with instrumentation

    Procedure: posterolateral spinal fusion with instrumentation

  • Experimental
    3

    10 subjects to receive middle dose of NeoFuse

    Biological: NeoFuse

  • Active comparator
    4

    3 subjects standard posterolateral spinal fusion with instrumentation

    Procedure: posterolateral spinal fusion with instrumentation

  • Experimental
    5

    10 subjects to receive highest dose of NeoFuse

    Biological: NeoFuse

  • Active comparator
    6

    3 subjects with standard posterolateral spinal fusion with instrumentation

    Procedure: posterolateral spinal fusion with instrumentation

Interventions

  • BiologicalRexlemestrocel-lStudies of Rexlemestrocel-lRexlemestrocel-l pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

    Also known as: Spinal Fusion, Stem Cells

  • Procedureposterolateral spinal fusion with instrumentation

    autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

    Also known as: Spinal Fusion, Controls

06

What researchers measure

Primary outcomes

  1. To determine the safety of NeoFuse (allogeneic mesenchymal precursor cells [MPCs]) when combined with MasterGraft Resorbable Ceramic Granules as a carrier for posterolateral lumbar fusion with instrumentation.

    Time frame: 30 days

Secondary outcomes

  1. To evaluate the overall fusion success of the use of NeoFuse plus carrier compared to autograft in the same patient

    Time frame: 3 years

  2. To assess CT scan as a pilot measure of fusion for use in the pivotal study

    Time frame: 3 years

  3. To provide preliminary data to support dose selection

    Time frame: 3 years

07

Study locations

1 site
  • Hospital for Special Surgery
    New York, New York 10021, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2007
First posted
Oct 26, 2007
Start
Oct 2007
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00549913
Lead sponsor
Mesoblast, Ltd.
Responsible party
Sponsor
First posted
Oct 26, 2007
Start date
Oct 2007
Primary completion
Aug 2013
Completion
Sep 2013
Last update
Jun 29, 2020

Study contacts

Donna Skerrett, MD
study director · Mesoblast, Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rexlemestrocel-l

Start the discussion